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Abstract: C-peptide has long been thought to be an inert byproduct of insulin production, 
but it has become apparent, and accepted, that C-peptide has important biological properties. 
C-peptide displays beneﬁ  cial effects in many tissues affected by diabetic complications, such 
as increased peripheral blood ﬂ  ow and protection from renal damage. However, the mecha-
nisms mediating these effects remain unclear. C-peptide interacts with cellular membranes at 
unidentiﬁ  ed sites distinctive of the insulin family of receptors, and signals to multiple targets 
known to play a role in diabetes and diabetic complications, such as Na+/K+-ATPase and NOS. 
In general, the physiological and molecular effects of C-peptide resemble insulin, but C-peptide 
also possesses traits separate from those of insulin. These basic studies have been conﬁ  rmed in 
human studies, suggesting that C-peptide may lend itself to clinical applications. However, the 
molecular and physiological properties of C-peptide are not completely elucidated, and large 
clinical studies have not begun. In order to further these goals, we critically summarize the 
current state of knowledge regarding C-peptide’s renal and vascular effects and the molecular 
signaling of C-peptide.
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Introduction
Diabetes mellitus (shortened as diabetes) is a class of diseases where an individual 
cannot properly maintain plasma glucose levels. There are two main types of diabetes, 
type 1 and type 2. Type 1 diabetes is characterized by a lack of insulin due to loss of 
beta cells in the pancreatic islets of Langerhans, whereas type 2 diabetes is typiﬁ  ed by 
a loss of response to insulin. Type 2 diabetes progresses through two stages. First there 
is a loss of target tissue insulin action (termed insulin resistance) that then results in 
increased insulin production (hyperinsulinemia). Eventually the second stage is reached 
when the islets of Langerhans cannot maintain such a high level of insulin production, 
and “pancreatic exhaustion” sets in causing insulin production to cease. Although the 
diseases have unique etiologies, several long-term complications are associated with 
both types of diabetes. Intensive treatment of hyperglycemia signiﬁ  cantly prevents 
diabetic complications (DCCT 1993), but glycemic control does not offer sufﬁ  cient 
protection from the development of complications.
Besides hyperglycemia, other causal factors appear to contribute to the develop-
ment of diabetic complications. One such factor is the proinsulin connecting peptide, 
C-peptide. C-peptide is a cleavage product of insulin synthesis created in the pancreas 
as part of insulin production, and is released into the circulation with insulin. The 
average physiological blood concentrations of C-peptide are in the low nM levels 
in healthy individuals (Samnegard and Brundin 2001). When, as in type 1 diabetes 
and late type 2 diabetes, insulin synthesis is impaired, synthesis of C-peptide is 
similarly impaired. Exogenous C-peptide has been shown to improve the function of 
many tissues commonly affected by diabetes complications (Lindstrom et al 1996; Biologics: Targets & Therapy 2008:2(3) 442
Nordquist et al
Johansson et al 2000; Chakrabarti et al 2004; Sima and Li 
2006), a development supported by the fact that pancreatic 
and islet of Langerhans transplantation, restoring not only 
insulin secretion, but also secretion of C-peptide, will pre-
vent and even reverse diabetic complications (Fiorina et al 
2003a, 2003b, 2005a, 2005b; Lee et al 2006; Venturini 
et al 2006). Hence, C-peptide deﬁ  ciency has successively 
emerged as a possible mechanism for the development of the 
disproportionate burden of complications affecting insulino-
penic diabetes patients. In this paper, some of the beneﬁ  cial 
renal and vascular effects of C-peptide are reviewed, as well 
as the current knowledge regarding C-peptide-mediated 
molecular mechanisms.
Beneﬁ  cial effects of C-peptide
Circulatory beneﬁ  ts
It has long been known that diabetes mellitus patients suf-
fer an increased risk of developing, as well as accelerating 
atherosclerosis – the principal cause of heart attack, stroke 
and gangrene of the extremities (Brownlee 2001). Microan-
giopathy, atherosclerosis, and abnormalities in small vessel 
function significantly contribute to the development of 
diabetes-induced morbidity (Jensen et al 1989). During the 
development of atherosclerosis, pathological proliferation 
and migration of vascular smooth muscle cells are necessary 
to form atherosclerotic plaques. C-peptide has been shown 
to prevent vascular dysfunction in diabetic rats (Ido et al 
1997), and to reduce proliferation of smooth muscle cells 
exposed to high glucose (Kobayashi et al 2005; Cifarelli 
et al 2008), a reduction that may suppress diabetes-induced 
atherosclerosis. It should be noted that under normoglycemic 
conditions C-peptide stimulates cultured smooth muscle cell 
proliferation (Walcher et al 2006).
Effects on nitric oxide and vasodilation
More than thirty years ago, impaired circulation, relative 
tissue hypoxia, and an impaired maximal oxygen uptake 
were reported in insulinopenic diabetes (Ditzel and Standl 
1975). Shortly after induction of diabetes in lambs, coronary 
vascular resistance is elevated (Lee and Downing 1979), 
and diabetic animals are prone to develop increased total 
peripheral resistance and hypertension (Bell et al 2006). 
Administration of C-peptide restores diabetes-impaired 
skeletal muscle perfusion (Johansson et al 1992a), improves 
capillary skin red blood cell velocity (Forst et al 1998), and 
myocardial blood perfusion (Hansen et al 2002) as well as 
pancreatic islet arteriole diameter (Nordquist et al 2008b). In 
type 2 diabetes, C-peptide concentrations correlate with the 
presence of coronary artery disease and peripheral vascular 
disease (Sari and Balci 2005). The C-peptide-induced beneﬁ  -
cial effects are, however, not restricted to the diabetic state. 
Surprisingly, in myocardial ischemia-reperfusion, C-peptide 
has been shown to exert cardioprotective effects through 
nitric oxide (NO) release (Young et al 2000).
Effects on erythrocyte deformability
When erythrocytes are deformed by the narrow space in 
the capillaries, they release adenosine triphosphate (ATP) 
(Sprague et al 1996). The ATP released from the erythrocyte 
stimulates NO synthesis and release from vascular endo-
thelial cells, an event that will regulate vascular resistance 
and improve oxygenation (Sprague et al 2003). In diabetes, 
erythrocyte deformability is impaired (Brown et al 2005) and 
erythrocyte aggregation increases. The impaired deformabil-
ity results in increased blood viscosity and decreases capillary 
blood ﬂ  ow and oxygen availability in the tissue. C-peptide 
levels have been suggested to positively correlate with eryth-
rocyte deformability (De La Tour et al 1998). Decreased 
membrane sodium, potassium adenosine triphosphatase 
(Na+/K+-ATPase) activity in erythrocytes is associated with 
diabetic complications (Raccah et al 1996; De La Tour et al 
1998), and there are indications that C-peptide concentrations 
correlate with erythrocyte Na+/K+-ATPase activity in type 1 
as well as type 2 diabetic subjects (De La Tour et al 1998). 
C-peptide is known to ameliorate the impaired deformability 
of erythrocytes in blood drawn from insulinopenic diabetic 
patients, and ouabain-inhibition of this effect suggests that 
the C-peptide-induced effects on erythrocyte deformability 
are mediated through restoration of the diabetes-impaired 
Na+/K+-ATPase activity (Kunt et al 1999). Recently, it was 
shown by Meyer and colleagues (2008) that in the presence 
of metal ions, C-peptide promotes the release of ATP from 
erythrocytes, and that this release is mediated via activation 
of the GLUT1 transporter.
Renoprotection
Early in the development of diabetic nephropathy, the glo-
merular ﬁ  ltration rate (GFR) increases. Diabetes-induced 
glomerular hyperﬁ  ltration has been proposed as an indepen-
dent risk factor for the development of renal complications, 
and it is well known that C-peptide prevents hyperﬁ  ltration 
as well as renal damage in experimental diabetes. C-peptide 
reduces glomerular hyperﬁ  ltration in diabetic patients, and 
long-term substitution therapy improves renal function 
(Johansson et al 1992b, 2000). In animal models of diabetes 
mellitus, exogenous C-peptide has been shown to reduce Biologics: Targets & Therapy 2008:2(3) 443
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diabetes-induced glomerular hyperﬁ  ltration and decrease 
albuminuria (Samnegard et al 2001, 2005; Huang et al 2002; 
Rebsomen and Tsimaratos 2005; Maezawa et al 2006). 
Structurally, renal glomerular hypertrophy and mesangial 
matrix expansion is prevented by C-peptide treatment, 
and it has been shown by Maezawa and colleagues (2006) 
that podocyte collagen gene expression is normalized by 
C-peptide treatment in a mouse model of type 1 diabetes 
(Samnegard et al 2001, 2005).
The rat C-peptide carboxy-terminal penta-fragment 
EVARQ has been shown to abolish diabetes-induced glo-
merular hyperﬁ  ltration. C-peptide and the penta-fragment 
both reduce diabetic hyperﬁ  ltration (Nordquist et al 2007). 
Hence, it is possible that the ﬁ  ve amino acid sequence of the 
carboxy-terminal of C-peptide is the sequence, or one of the 
sequences, mediating the normalizing effect on GFR in these 
diabetic rats. It is common that proteins have deﬁ  ned func-
tional sites. A fragment of gonadotropin-releasing peptide 
displays increased activity compared to the intact peptide 
(Sandow and Konig 1979; Ramasharma et al 1988). Similar 
to C-peptide gastrin, cholecystokinin and osteogenic growth 
peptide, have active sites in their C-terminal penta-peptides 
(Portelli and Renzi 1973; Yaijma et al 1977; Bab et al 1999; 
He et al 2004).
Afferent arteriolar constriction
The glomerular microcirculation is regulated to a great extent 
through alterations in the vascular resistance of the afferent 
and efferent arterioles. In insulinopenic diabetes, afferent 
diameter is increased (Ikenaga et al 2000). C-peptide con-
stricts isolated renal afferent arterioles from diabetic mice, 
but not from normoglycemic animals (Nordquist et al 2008a). 
Constriction of the afferent arteriole lowers glomerular ﬁ  ltra-
tion pressure and thus decreases GFR. However, C-peptide 
does not appear to diminish renal blood ﬂ  ow (Huang et al 
2002, Samnegard et al 2004). Taken together, these results 
suggest that C-peptide reduces diabetes-induced glomerular 
hyperﬁ  ltration at least partly via constriction of the afferent 
glomerular arteriole, but with a simultaneous dilation of the 
efferent arteriole that counterbalances the effect on renal 
blood ﬂ  ow. It should be noted that efferent dilation and 
increased afferent vascular tone have also been reported for 
insulin (Juncos and Itos 1993).
Tubuloglomerular feedback
It has previously been postulated that diabetic hyperﬁ  ltra-
tion occurs due to alterations in tubuloglomerular feedback 
(TGF) (Vallon et al 1995; Thomson et al 2001). TGF is an 
intrarenal mechanism that stabilizes GFR, and thus the 
tubular Na+-load to match the tubular Na+ handling capac-
ity. The anatomical prerequisite for TGF is the return of 
the tubule to its own glomerulus. These, together with the 
macula densa (MD) make up the juxtaglomerular apparatus. 
The MD consists of specialized epithelial cells localized 
where the returning tubule passes the glomerulus, and 
constitutes a sensor mechanism for Na+ by sensing Cl−, 
which relates to Na+ levels. Increased tubular ﬂ  ow rate 
will increase the tubular NaCl load, which is sensed by the 
MD, and results in a constriction of the afferent arteriole. 
However, the afferent constriction caused by C-peptide was 
demonstrated in isolated arterioles, where the arteriole is 
not set up with an intact tubulus and thus is independent 
of TGF. In addition, it was recently shown by Sallstrom’ 
et al that TGF does not mediate diabetes-induced hyperﬁ  l-
tration, since diabetes-induced glomerular hyperﬁ  ltration 
occurs in adenosine A1-receptor-deﬁ  cient mice known to 
lack a functional TGF mechanism (Sallstrom et al 2007). 
If TGF is not the mediator of diabetic hyperﬁ  ltration, it is 
unlikely that C-peptide would exert its effect on ﬁ  ltration 
via a TGF-dependent mechanism. Therefore, a possible 
conclusion is that C-peptide exerts its effect directly on the 
glomerular afferent arterioles.
Many aspects remain to be investigated
Blood ﬂ  ow is differentially affected in the kidney vascu-
lature versus peripheral vasculature in the diabetic state. 
Multiple studies show normalizing effects of C-peptide on 
diabetes-impaired blood perfusion and blood cell velocity 
(Forst et al 1998; Johansson et al 2003). However, in these 
studies, C-peptide reverses diabetes-induced decreases 
in peripheral blood perfusion, whereas in renal vessels 
C-peptide reverses diabetes-induced increases in blood ﬂ  ow 
(Bank and Aynedjian 1993; Wang et al 1993; Komers et al 
1994). It remains to be determined whether these beneﬁ  cial, 
but seemingly opposing effects of C-peptide reﬂ  ect tissue-
speciﬁ  c mechanisms.
Another aspect of C-peptide as a vasoactive substance is 
that the vasoconstrictive effect of C-peptide takes consider-
ably longer time to develop compared to well known con-
strictors such as angiotensin II or norepinephrine (Nordquist 
et al 2008a). An explanation of this could be a sequential 
cascade of intracellular events leading to vasoconstriction. 
Although C-peptide clearly possesses a reducing effect on 
diabetic hyperﬁ  ltration, there is still no effector, no recep-
tor, and no downstream signalling cascade reported for this 
phenomenon. So what are possible causes of the effect of Biologics: Targets & Therapy 2008:2(3) 444
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C-peptide on hyperﬁ  ltration? In the next section we review 
likely candidates mediating C-peptide’s physiological 
properties.
C-peptide cellular signaling
A putative G protein-coupled receptor
The ﬁ  rst report of a possible receptor was published in 1986 
when rat C-peptide I was found to bind speciﬁ  cally to cul-
tured rat islet tumor B-cells (Flatt et al 1986). Early studies 
suggested that C-peptide mimics insulin action, but that its 
action on the renal Na+/K+-ATPase is completely abolished 
by pretreatment with pertussis toxin (PTX) (Ohtomo et al 
1996). PTX is an inhibitor of Gαi/o family of heterotrimeric G 
proteins (Katada and Ui 1982; West et al 1985), and has been 
shown to eliminate nearly all C-peptide signaling activities 
(Rigler et al 1999; Kitamura et al 2001; Zhong et al 2005; 
Al-Rasheed et al 2006; Lindahl et al 2007), something that 
strongly suggests that the putative C-peptide receptor is a 
seven transmembrane G protein-coupled receptor (GPCR).
Identiﬁ  cation of GPCRs is not an easy task, and to date 
the cell surface receptor(s) for C-peptide remain unknown. 
However, multiple studies have been conducted via manipu-
lating the ligand–C-peptide (Ido et al 1997; Ohtomo et al 
1998; Rigler et al 1999). Initially, rat and human C-peptides, 
but not pig C-peptide, were shown to act like insulin and 
return elevated glucose-mediated blood ﬂ  ow to normal in 
two models (Ido et al 1997). The structure of C-peptide 
was examined by circular dichroism revealing that human 
and rat C-peptide begin and end with alpha helical domain 
linked by a ﬂ  exible glycine rich domain containing a distinc-
tive proline kink in the middle of the sequence; sadly pig 
C-peptide was not examined (Ido et al 1997). Additionally, 
Ido and colleagues indicated that the reverse sequence, all 
D amino acids, and the middle glycine rich section had 
similar effects as full length rat and human C-peptide. It 
should be noted that if there is a receptor involved, then the 
D amino acids should be inert. The unexpected data lead 
the authors to conclude that, contrary to previous studies 
(Ohtomo et al 1996), the effects are not receptor dependent 
and that C-peptide enters cells similar to some bacterial 
proteins (Ido et al 1997). Shortly thereafter, activity of the 
glycine rich region was conﬁ  rmed when examining renal 
Na+/K+-ATPase activity (Ohtomo 1998). The glycine rich 
region was 20% less effective than full length C-peptide, but 
interestingly, the last 4 amino acids were only 8% less active 
than full length C-peptide, and the terminal penta-peptide 
had slightly greater activity than the full length peptide. 
Moreover, randomly scrambled C-peptide and the D-amino 
acid penta-peptide had no effect (Ohtomo et al 1998). These 
data indicate that indeed sequence speciﬁ  city and chirality, 
an essential component of ligand-receptor interactions, are 
essential for C-peptide activity.
Binding studies demonstrated that C-peptide speciﬁ  -
cally binds to human renal tubular cells, ﬁ  broblasts from 
the upper arm, and saphenous vein endothelial cells, but not 
umbilical cord endothelial cells (Rigler et al 1999). Rigler 
and colleagues found that the half maximal binding (B50) 
was 0.3 nM and Bmax = 0.9 nM. Importantly, C-peptide 
binding was not displaced by all D-amino acid C-peptide, 
insulin, proinsulin, or insulin like growth factor (IGF) I and 
II; however, the terminal penta-peptide was as efﬁ  cient in 
displacement as full length C-peptide (Rigler et al 1999). 
These data support the theory that the last 5 amino acids 
mediate the binding of C-peptide to its receptor and that it 
has a unique receptor independent of the insulin family of 
receptors. Lastly, Rigler and colleagues (1999) conﬁ  rmed 
earlier studies that the majority of the receptor is a Gαi/o 
coupled receptor via use of PTX. However, there appears to 
be a small pool of receptors that are PTX insensitive, suggest-
ing that C-peptide either has two receptors or a single GPCR 
that couples to Gαi/o and another Gα subunit (Rigler et al 
1999). More recently, multiple studies have conﬁ  rmed that 
the secondary structure of C-peptide is essential for proper 
signaling (Kitamura et al 2002; Li et al 2003; Walcher et al 
2006), and that the penta-peptide mimics C-peptides effects 
(Zhong et al 2005). Therefore, the earlier studies by Ido and 
colleagues (1997) have not been repeated, and it appears that 
C-peptide does bind to yet unidentiﬁ  ed receptors.
Recently, the coupling of the C-peptide receptor to Gαi 
has been proven examining C-peptide-mediated activation of 
Gαi (Al-Rasheed et al 2006). C-peptide, but not scrambled 
C-peptide, caused the nonhydrolyzable GTP analogue 
35S-GTPγS to bind to Gαi, indicating that C-peptide activates 
Gαi. Unfortunately no other G-protein was examined in this 
assay, so it is unknown if the PTX insensitive receptor pool 
is acting through a different G-protein or a different class 
of receptors. However, these data prove that stimulation of 
cells with C-peptide activates Gαi.
In contrast to the studies suggesting that C-peptide acts 
through a GPCR, studies using isolated L6 rat myoblast 
membranes demonstrated that insulin and C-peptide, but 
not scrambled C-peptide, increased membrane associated 
tyrosine kinase activity (Grunberger et al 2001). Moreover, 
C-peptide enhances insulin receptor tyrosine kinase activ-
ity, although with very low level of activation. These data 
allowed for theories to be generated about C-peptide binding Biologics: Targets & Therapy 2008:2(3) 445
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to, or merely activating, the insulin receptor. In response to 
the re-emergent theory that C-peptide binds to the insulin 
receptor, surface plasma resonance (SPR), a technique 
that detects protein-protein interactions, was used to show 
little to no binding of C-peptide to insulin or IGF-I recep-
tors (Henriksson et al 2006). Moreover, Henricksson and 
colleagues demonstrated that insulin, but not C-peptide, 
activates the glucokinase and insulin promoter. Therefore, 
although the receptors signal similarly in physiological 
conditions, the molecular mechanisms are not identical and 
C-peptide binds to a unique receptor.
In support of the GPCR theory, rhodamine-labeled 
C-peptide binds to Swiss-3T3 and HEK-293 cells and 
internalizes in a temperature and PTX dependent mecha-
nism (Lindahl et al 2007). Additionally, pre-incubation of 
C-peptide with a C-peptide antibody or unlabeled C-peptide 
inhibits rhodamine-labeled C-peptide binding. In order to 
identify a C-peptide receptor, Lindahl and colleagues (2007) 
utilized Biacore sensor chips, SPR, and matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) 
to identify C-peptide binding partners from HEK-293 
cell extracts. Intracellular proteins were found to bind to 
C-peptide, but although the rhodamine-labeled C-peptide was 
found to internalize, receptor mediated endocytosis does not 
expose the ligand to the cytosol. Thus, these data need to be 
examined further to exclude false positive associations, since 
the ligand may never be exposed to those proteins unless 
C-peptide is entering the cells in a nonclassical manner as 
proposed by Ido and colleagues (1997).
In conclusion, it is clear that C-peptide binds to receptor(s) 
distinctive of the insulin family of receptors. Additionally, one 
of the receptors stimulates Gαi. Collectively, the data strongly 
suggest that the receptor is a GPCR, in fact this amount of evi-
dence was sufﬁ  cient for classifying receptors before the advent 
of cloning. However, since the receptor is still unknown this is 
not a deﬁ  nitive conclusion. To further complicate the potential 
identity of the C-peptide receptor, activators of G-protein 
signaling (AGS) family of proteins are known to activate Gαi 
independently of GPCRs (Blumer et al 2005). Therefore the 
precise nature of the C-peptide receptor cannot be determined 
from the literature and requires further investigation.
Receptor-mediated signal 
transduction
As mentioned previously, the physiological properties mir-
ror, for the most part, insulin-mediated effects. In fact stud-
ies conducted in L6 rat myoblasts indicate that C-peptide 
signals nearly identically to insulin, except in regard to 
phosphorylation of Akt (Grunberger et al 2001). These data 
along with the physiological effects of C-peptide were strong 
contributing factors to the proposal that C-peptide signals 
through the insulin receptor. In this section we will review the 
general signaling of C-peptide. However, it must be noted 
that it has already become evident that there are cell-speciﬁ  c 
signaling mechanisms. For example, in rat medullary thick 
ascending limb (mTAL) cells C-peptide causes translocation 
of protein kinase C (PKC) α, but not PKCδ, ε, or ζ, to the 
plasma membrane (Tsimaratos et al 2003), and in human 
renal tubular cells C-peptide causes translocation of PKCδ 
and ε, but not PKCα, γ, ζ, and θ (Zhong et al 2005). Similar 
discrepancies have been shown for Akt (Grunberger et al 
2001; Zhong et al 2005) and the NOS isoforms (Kitamura 
et al 2003; Wallerath et al 2003; Li et al 2004). Therefore, 
we will include the cell types when describing the signaling 
pathways, and synthesize a generic signaling paradigm for 
C-peptide.
Na+/K+-ATPase
Initial studies demonstrated that C-peptide activates the 
renal Na+/K+-ATPase through a PTX and FK-506-dependent 
mechanism (Ohtomo et al 1996). FK-506 is a speciﬁ  c inhibi-
tor of calcineurin (also known as protein phosphatase 3 and 
formerly called protein phosphatase 2B), which has been 
shown to be involved in activation of Na+/K+-ATPase (Lea 
et al 1994). Importantly, calcineurin is activated by binding to 
calmodulin after increased intracellular Ca2+ levels (Klee et al 
1979) indicating that C-peptide must increase intracellular 
Ca2+ levels. This was conﬁ  rmed in bovine aortic endothelial 
cells (Wallerath et al 2003). Additionally, extensive studies in 
human renal tubular cells indicate that the L-type Ca2+ chan-
nel blockers nifedipine and verapamil, as well as the phospho-
lipase C (PLC) inhibitor U73122 inhibit C-peptide-mediated 
signaling, thus indicating that the Ca2+ entry is through L-type 
Ca2+ channels (Zhong et al 2005). The activation of PLC and 
Ca2+ inﬂ  ux provides a mechanism for C-peptide-mediated 
activation of classical PKC family members, such as PKCα. 
In rat mTAL cells C-peptide-mediated Na+/K+-ATPase 
activity and phosphorylation of the α-subunit of Na+/K+-
ATPase is blocked by the general PKC inhibitor GF109203X 
(Tsimaratos et al 2003). Further studies in human renal 
tubular cells conﬁ  rm the role of PTX and GF109203X, but 
also show that phosphorylation of the α-subunit of Na+/K+-
ATPase is blocked by PD98059, a MEK inhibitor (Zhong 
et al 2004). Furthermore, the C-peptide-mediated phosphory-
lation of the α-subunit of Na+/K+-ATPase has been shown 
to be a threonine residue residing within an ERK consensus Biologics: Targets & Therapy 2008:2(3) 446
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site. This suggests that ERK, not PKC, is phosphorylating the 
Na+/K+-ATPase (Zhong et al 2004) and that PKC is involved 
in activating ERK, as described in the next section.
These data collectively suggest that C-peptide activates 
PLCβ2 through Gβγ subunits associated with Gαi (Katz et al 
1992; Wu et al 1993), and that C-peptide activates L-type 
Ca2+ channels through Gβγ subunits (Viard et al 1999). 
The activation of the L-type Ca2+ channel by Gβγ alone is 
rather minimal and requires phosphatidylinositol 3-kinase 
(PI3K), which is activated by C- peptide (Grunberger et al 
2001; Kitamura et al 2001; Li et al 2003; Al-Rasheed et al 
2006; Walcher et al 2006), to allow for a full Ca2+, transient 
(Viard et al 1999). Additionally there is a role for PKC in 
the Gβγ-mediated activation of L-type Ca2+ channels (Viard 
et al 1999). Since PKCδ and ε do not require Ca2+ for acti-
vation they may play a role in enhancing the Ca2+ transient 
since they translocate to the membrane after stimulation 
with C-peptide (Zhong et al 2005). However, the level of 
C-peptide-mediated activation of the L-type Ca2+ channel 
was not compared to a positive control, and no experiments 
examining the mechanism of C-peptide-mediated Ca2+ entry 
into cells has been conducted. Thus it is unknown if PKC 
and PI3K are needed for C-peptide-mediated activation of 
L-type Ca2+ channels and subsequent PKCα activation. As 
described in the next section, PI3K is most likely needed 
for activation of ERK, which in humans is a necessary 
component of C-peptide-mediated phosphorylation of the 
α-subunit of Na+/K+-ATPase (Zhong et al 2004). Further 
experiments are required to deﬁ  nitively describe the signaling 
cascade from the C-peptide receptor(s) to Na+/K+ ATPase; 
the current model is shown in Figure 1.
MAPKs
Activation of mitogen-activated protein kinases (MAPKs) is 
common to many signaling molecules; there are three major 
MAPK proteins: ERK, p38, and JNK. However, the mecha-
nism of receptor-mediated, especially GPCR-mediated, 
activation of MAPKs is not uniform and is still contested. 
C-peptide activates ERK, p38, and JNK, but as detailed 
below only ERK is consistently shown to be activated by 
C-peptide.
C-peptide signaling to ERK was first reported in 
2001 (Grunberger et al 2001; Kitamura et al 2001). In 
Swiss 3T3 fibroblasts Kitamura and colleagues (2001) 
demonstrated that C-peptide-mediated phosphorylation of 
ERK has an EC50 = 0.25 ± 0.05 nM, which is in accordance 
with the B50 = 0.3 nM (Rigler et al 1999), and ERK is 
phosphorylated within 10 min. Additionally, signaling to 
ERK is completely inhibited by PTX, nearly abolished by 
GF109203X, and inhibited by 50% by the PI3K inhibitor 
Figure 1 Molecular mechanisms of C-peptide-mediated activation of Na+/K+ ATPase. This cartoon simpliﬁ  es the signaling cascade resulting in activation of the Na+/K+ ATPase. 
Arrows represented signaling cascades. The activation of ERK is not completely understood. For simplicity it drawn with a single arrow from PKCα; however, it is known not 
to be a direct mechanism. Similarly, the precise role of calcineurin in regulation of the Na+/K+-ATPase is unknown, and is represented here by a simple arrow. The question 
mark (?) indicates simpliﬁ  ed or unknown pathways.
Abbreviations: PLC, phospholipase C; PKCα, protein kinase Cα; ERK, extracellular regulated kinase; CAM, calmodulin.
R?
? R?
?
Gα i Gβγ
Na+/K+
ATPase
PLC
[Ca2+]i
Calcineurin
PKCα
P
Na+
K+
C-peptide
ERK
?
?
Ca+
L-Type 
Ca2+
channel PKCα
CaMBiologics: Targets & Therapy 2008:2(3) 447
Proinsulin C-peptide and diabetes mellitus
wortmannin. Thus, indicating that Gαi and PKC mediate 
C-peptide-dependent phosphorylation of ERK, and that PI3K 
also has a signiﬁ  cant role. Grunberger and colleagues (2001) 
demonstrated in L6 rat myoblasts a similar concentration 
response curve that is bell-shaped and showed no response 
at 10 nM and higher concentrations of C-peptide. This bell-
shaped concentration-response curve is unusual; however, 
the bell-shaped curve is reported throughout the C-peptide 
literature. Not all studies with C-peptide result in a bell-
shaped curve. For instance, C-peptide stimulation of mouse 
lung capillary endothelial cells results in a standard sigmoidal 
activation curve for ERK (Kitamura et al 2002). The potential 
physiological consequences of the bell-shaped curve in regards 
to diabetes treatment will be discussed in the conclusion.
The studies by Kitamura and colleagues (2002, 2003) 
indicate that C-peptide increased the phosphorylation of 
ERK and p38, but not JNK. These studies were reinforced 
via kinase assays, and thus are the ﬁ  rst conclusive proof 
that C-peptide activates ERK and p38 (Kitamura et al 
2002). C-peptide-mediated activation of ERK and p38 was 
conﬁ  rmed in rat aortic endothelial cells (Kitamura et al 
2003). In contrast, in human renal tubular cells C-peptide 
increases phosphorylation of ERK and JNK, but not p38 
(Zhong et al 2005). These and other data suggest that ERK 
is the primary MAPK activated by C-peptide. Via use of 
speciﬁ  c inhibitors, Kitamura and colleagues demonstrated 
that ERK leads to phosphorylation of RSK1, but not MSK1. 
C-peptide-mediated phosphorylation and activation of RSK1 
also occurs in L6 rat myoblasts (Grunberger et al 2001). 
Importantly, RSK1 is downstream of ERK and PDK1, and is 
involved in multiple signaling cascades including inactivation 
of glycogen synthase kinase (Hauge and Frodin 2006). Thus 
C-peptide-mediated activation of ERK may be important in 
processing glucose.
The most complete C-peptide-mediated signaling to 
ERK has been worked out in vascular smooth muscle cells. 
C-peptide-mediated ERK and JNK phosphorylation abso-
lutely requires PLC, L-type Ca2+ channels, PKC, and MEK 
activity (Walcher et al 2006). Furthermore, C-peptide signal-
ing to ERK is signiﬁ  cantly reduced by treatment with the src 
family kinase inhibitor PP2 and the PI3K inhibitor LY294002 
(Walcher et al 2006). PP2 is a dirty drug (Bain et al 2007), 
however Walcher and colleagues also used siRNA demon-
strating that c-src is involved in C-peptide-mediated phos-
phorylation of ERK. Additionally, PP2 signiﬁ  cantly, but not 
completely, blocks C-peptide mediated generation of PIP3, 
indicating that src is involved in the activation of PI3K. 
Activation of ERK in vascular smooth muscle cells leads 
to cellular proliferation and increased cyclin D1 expression 
(Walcher et al 2006).
Collectively the data indicate that C-peptide is a potent 
stimulant of MAPKs, speciﬁ  cally ERK. Most of the studies 
have used insulin or PDGF as a positive control and found 
C-peptide to activate ERK to a much lesser extent; however, 
how C-peptide acts in comparison to ligands with similarly 
expressed receptors has not been examined. It is known 
that the C-peptide receptor(s) are less dense than the insulin 
receptor (Rigler et al 1999). Although there appears to be 
tissue speciﬁ  city as to which MAPKs are activated, in all 
cases ERK is activated. ERK phosphorylation is a common 
occurrence for Gαi-coupled receptors (L’Allemain et al 
1991), and can occur through multiple pathways including 
through Gαi (Hedin et al 1999) and through Gβγ (Crespo 
et al 1994; Koch et al 1994) activation of PI3K (Stoyanov 
et al 1995; Hawes et al 1996; Lopez-Ilasaca et al 1997). 
Hedin and colleagues (1999) demonstrate that the Gαi-
dependent mechanism is independent of Ras and PI3K, but 
requires PKC, which may explain the 50% inhibition seen 
with wortmannin (Kitamura et al 2001) and allow for more 
traditional roles for PKC (Schonwasser et al 1998) and c-src 
(Luttrell et al 1996) as is eluded to by Walcher and colleagues 
(2006). These accepted pathways partially unite the disparate 
C-peptide signaling pathways into one mechanism. However, 
the precise molecular mechanisms of how ERK is activated 
remain unknown.
In conclusion, the use of PTX, PI3K, and MEK inhibi-
tors suggest that the mechanism involves the classical Ras-
Raf/MEK/ERK cascade that is activated by Gβγ-mediated 
activation of PI3K. However, this does not account for 
how PKC and c-src are involved in activating this cascade. 
Thus, although C-peptide clearly activates ERK through a 
Gαi-mediated mechanism that involves PI3K, the multiple 
cell types used, lack of standardized experiments across cell 
types, and lack of a known receptor make it impossible to 
clearly unite all of the data into a single pathway. Our experi-
ence indicates that signaling to ERK is cell type-dependent 
(Escano et al 2008). Additionally, the disparities between the 
phosphorylation of p38 and JNK support the idea that cell 
type dependent mechanisms are involved in the activation 
of the MAPKs. Thus, we are hesitant to combine all of the 
data into one pathway.
NO synthase
There are three isoforms of nitric oxide synthase (NOS): 
iNOS, nNOS, and eNOS (Mashimo and Goyal 1999). 
C-peptide has been shown to activate eNOS in rat and bovine Biologics: Targets & Therapy 2008:2(3) 448
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aortic endothelial cells (Kitamura et al 2003; Wallerath 
et al 2003). Wallerath and colleagues demonstrated that 
C-peptide rapidly generates cGMP in a concentration-
dependent manner. cGMP levels peak within 5 min and by 
10 min the levels are similar to baseline levels, which can 
be attributed to phosphodiesterases degrading the cGMP. 
Furthermore, Wallerath and colleagues (2003) indicate that 
C-peptide-mediated increase in cGMP levels were abrogated 
by the NOS inhibitor L-NNA and by Ca2+ free media. This 
suggests that eNOS is involved in C-peptide-mediated NO 
production. C-peptide did not increase eNOS mRNA. In 
contrast, Kitamura and colleagues (2003) demonstrated that 
C-peptide transiently increases eNOS, but not iNOS, and 
that mRNA levels and eNOS protein levels are increased 
for up to 6 hours. eNOS expression was blocked by inhibit-
ing gene transcription with actinomycin D and inhibition of 
MEK. Thus, Kitamura and colleagues (2003) indicate that 
the ERK MAPK pathway is important in C-peptide-mediated 
generation of NO. Additionally, Kitamura and colleagues 
(2003) observe NO production utilizing the NO sensitive 
dye DAF-2. The procedure followed, 3 hours of treatment 
followed by washing and then exposure to DAF-2 for 
1 hour, cannot discriminate between the increased levels of 
eNOS generating increased basal NO and C-peptide-medi-
ated release of NO. Given that Wallerath and colleagues 
(2003) show that C-peptide-mediated production of cGMP 
occurs within 10 min, the DAF-2 results from Kitamura 
and colleagues are most likely due to the enhanced eNOS 
protein levels. Supporting, in part, the study by Kitamura 
and colleagues (2003), Li and colleagues (2004) indicate that 
24 hour exposure of human smooth muscle cells to C-peptide 
increases iNOS and eNOS mRNA and protein levels. Though 
generally reported to be a stimulator of NOS, C-peptide 
counteracts diabetes-induced increases in renal eNOS levels 
(Kamikawa et al 2008). The seeming contradictions in the 
data may be due to altered mechanisms in the diabetic state, 
cell type, or methodology, which is not standard between 
the studies. In summary, C-peptide, like insulin, is involved 
in generation of NO through activation of eNOS, but the 
mechanism is largely unknown.
NF-κB activation and protection 
of diabetic nephropathy
There are a few reports indicating that C-peptide acti-
vates nuclear factor κB (NF-κB) (Al-Rasheed et al 2006; 
Kitazawa et al 2006). In Swiss 3T3 cells inhibition of PKC 
inhibits NF-κB activation (Kitazawa et al 2006). In OK 
cells C-peptide protects against tumor necrosis factor α 
(TNF-α)-mediated apoptosis through an NF-κB mediated 
mechanism (Al-Rasheed et al 2006). C-peptide-mediated 
NF-κB activity was ablated by PTX and wortmannin, but 
not PD98059. Al-Rasheed and colleagues (2006) also 
demonstrate that C-peptide increases TRAF2, an NF-κB 
driven survival gene, and blocks high concentration TNF-
α-mediated decreased expression of TRAF2. Together the 
data indicate that C-peptide may activate NF-κB through a 
PKC- and PI3K-dependent phosphorylation of IκB that then 
leads to increased translation of NF-κB driven genes that 
can inhibit TNF-α-mediated signaling. It should be noted 
that recent data suggest C-peptide rather reduces NF-κB 
activation (Cifarelli et al 2008).
Importantly, TNF-α has been suggested in the patho-
genesis of diabetic nephropathy (Moriwaki et al 2007). 
Additionally, TNF-α is increased in diabetic nephropathy 
(Kalantarinia et al 2003) and correlates with urinary pro-
tein excretion (Moriwaki et al 2007). Injection of TNF-α 
decreases renal function (Schmidt et al 2007), and Moriwaki 
and colleagues (2007) demonstrated that inhibiting TNF-α 
reduces albuminuria in experimental diabetic rats. Therefore, 
C-peptide-mediated inhibition of TNF-α-mediated effects in 
renal cells may have clinical beneﬁ  ts.
Activation of RhoA and physiological 
consequences
C-peptide activates the small guanosine triphosphatase 
(GTPase) RhoA through an unknown mechanism in human 
renal tubular cells (Zhong et al 2005). Physiologically, Rho-
kinase, an effector of RhoA, is known to be responsible for 
mediating “Ca2+-sensitation”, a condition where smooth 
muscle constriction is enhanced in similar or lower levels of 
Ca2+ inﬂ  ux (Kimura et al 1996). Rho-kinase is of particular 
interest because it plays an important role in mediating vaso-
constriction in the kidney (Roos et al 2006). Additionally, 
RhoA/Rho-kinase regulates blood ﬂ  ow, GFR, and alters the 
function and structure of renal tubular epithelial cells and 
mesangial cells (Wakino et al 2005).
We have previously shown that the Rho-kinase inhibi-
tion with Y-27632 prevents the vasoconstrictive effects of 
C-peptide in isolated afferent arterioles, thus suggesting that 
C-peptide activates RhoA and consequently Rho-kinase in 
the renal vasculature (Nordquist et al 2008a). However, 
reduction of C-peptide-induced vasoconstriction by inhibition 
of Rho-kinase does not necessarily imply that C-peptide acti-
vates Rho-kinase (Figure 2). C-peptide is known to increase 
PKC and MAPKs, both of which are capable of mediat-
ing contraction (via CPI-17 and caldesmon, respectively Biologics: Targets & Therapy 2008:2(3) 449
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(Gerthoffer et al 1996; Walsh et al 2007; Sakai et al 2007). 
Additionally, MAPK has been linked to phosphorylation 
of the regulatory subunit of the myosin light chain in the 
same location as myosin light chain kinase (Roberts 2004). 
Moreover, Gαi-coupled receptors can activate integrin-linked 
kinase (ILK) through a PI3K-dependent pathway that results 
in phosphorylation of CPI-17 and the myosin light chain 
at the same site as myosin light chain kinase (Huang et al 
2006). Since inhibition of Rho-kinase allows for greater 
myosin phosphatase activity, which in turn will decrease 
the phosphorylation status of the regulatory subunit of the 
myosin light chain, it is possible that C-peptide induces 
phosphorylation of the myosin light chain through one of 
the aforementioned pathways, and that Y-27632 is only 
increasing the basal level of myosin phosphatase. Thus, more 
investigation is warranted into the link between C-peptide and 
RhoA/Rho-kinase activation in the renal vasculature.
Concluding remarks
Thus far, the results from C-peptide studies display several 
unexplored research directions and opportunities for novel 
therapeutic interventions. It is clear that C-peptide possesses 
beneﬁ  cial effects on diabetes-induced complications. This is 
supported by pancreas and islet of Langerhans transplantation 
in diabetic patients, restoring not only the patients’ insulin 
production, but also production of C-peptide. Thus, large 
scale clinical trials examining the beneﬁ  ts of C-peptide 
should be initiated in diabetic patients. In type 1 and stage 2 
type 2 diabetes restoring circulating C-peptide is most likely 
going to be beneﬁ  cial to the patient. However, the afore-
mentioned bell-shaped concentration response curve may, 
paradoxically, help potentiate insulin resistance. In many 
cases mid to high nanomolar concentrations of C-peptide 
signalled less than low nanomolar concentrations, which 
could reduce the physiological effect of C-peptide and may 
explain why the increased levels of C-peptide in phase 1 type 
2 diabetics is not beneﬁ  cial. This apparent paradox must be 
more fully examined before C-peptide is administered to 
hyperinsulinemic type 2 diabetic patients. Additionally, if 
this paradox is physiologically relevant then the level of C-
peptide administration would have to be carefully monitored, 
such as is done with insulin.
Finally, there are multiple basic and clinically relevant 
questions that remain unanswered. The identity of the 
receptor is clinically important, and the downstream sig-
nalling cascade, as currently known, does not fully explain 
amelioration of diabetes-induced complications. Further 
studies should be undertaken, investigating the intracellular 
Figure 2 Schematic illustrations of sequences of events leading to constriction. This schematic drawing illustrates possible downstream effects of C-peptide.
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effects of C-peptide. If the C-peptide receptor is a GPCR, 
then an agonist to the receptor can be generated. This is 
important since C-peptide may not be easily administered 
to patients, whereas a stable agonist may be able to be 
supplied as a once a day pill. Similarly, more fully under-
standing the cellular signaling of C-peptide may lead to 
novel interventions in diabetes associated diseases, such 
as nephropathy.
In conclusion, the ﬁ  eld of C-peptide biology has acceler-
ated greatly in the last 15 years. It is clear that C-peptide is 
biologically active, binds to cell surface receptors, and signals 
in a manner similar but unique from insulin. Physiologically, 
the effects are in some aspects similar to that of giving insu-
lin to type 1 diabetic patients; however, C-peptide appears 
to restore insulin-treated type 1 diabetic patients to normal 
physiology. Given that C-peptide is a hormone co-secreted 
with insulin, and thus is absent in type 1 diabetes, the ben-
eﬁ  cial effects of C-peptide are not surprising.
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